Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression

被引:582
作者
Basseres, D. S. [1 ]
Baldwin, A. S. [1 ]
机构
[1] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
关键词
NF-kappa B; IKK; cancer; cancer therapy; inhibitors; signal transduction;
D O I
10.1038/sj.onc.1209942
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Abundant data support a key role for the transcription factor nuclear factor-kappa B (NF-kappa B) signa ling pathway in controlling the initiation and progression of human cancer. NF-kappa B and associated regulatory proteins such as I kappa B kinase (IKK) are activated downstream of many onco-proteins and there is much evidence for the activation of NF-kappa B-dependent target genes in a variety of solid tumors and hematologic malignancies. This review focuses on the mechanisms by which the NF-kappa B pathway is activated in cancer and on the oncogenic functions controlled by activated NF-kappa B. Additionally, the effects of NF-kappa B activation in tumors relative to cancer therapy are also discussed.
引用
收藏
页码:6817 / 6830
页数:14
相关论文
共 153 条
[131]   Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis [J].
Sparmann, A ;
Bar-Sagi, D .
CANCER CELL, 2004, 6 (05) :447-458
[132]   Nucleolar sequestration of RelA (p65) regulates NF-κB-driven transcription and apoptosis [J].
Stark, LA ;
Dunlop, MG .
MOLECULAR AND CELLULAR BIOLOGY, 2005, 25 (14) :5985-6004
[133]   Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro [J].
Subhashini, J ;
Mahipal, SVK ;
Reddanna, P .
CANCER LETTERS, 2005, 224 (01) :31-43
[134]   Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma [J].
Tai, YT ;
Li, XF ;
Tong, X ;
Santos, D ;
Otsuki, T ;
Catley, L ;
Tournilhac, O ;
Podar, K ;
Hideshima, T ;
Schlossman, R ;
Richardson, P ;
Munshi, NC ;
Luqman, M ;
Anderson, KC .
CANCER RESEARCH, 2005, 65 (13) :5898-5906
[135]   Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation [J].
Takada Y. ;
Bhardwaj A. ;
Potdar P. ;
Aggarwal B.B. .
Oncogene, 2004, 23 (57) :9247-9258
[136]   A novel NF-κB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors [J].
Tanaka, A ;
Konno, M ;
Muto, S ;
Kambe, N ;
Morii, E ;
Nakahata, T ;
Itai, A ;
Matsuda, H .
BLOOD, 2005, 105 (06) :2324-2331
[137]   P53 stabilization is decreased upon NFκB activation:: A role for NFκB in acquisition of resistance to chemotherapy [J].
Tergaonkar, V ;
Pando, M ;
Vafa, O ;
Wahl, G ;
Verma, I .
CANCER CELL, 2002, 1 (05) :493-503
[138]   Epithelial-mesenchymal transitions in tumour progression [J].
Thiery, JP .
NATURE REVIEWS CANCER, 2002, 2 (06) :442-454
[139]   CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members [J].
Trompouki, E ;
Hatzivassiliou, E ;
Tsichritzis, T ;
Farmer, H ;
Ashworth, A ;
Mosialos, G .
NATURE, 2003, 424 (6950) :793-796
[140]   NF-κB activation in melanoma [J].
Ueda, Y ;
Richmond, A .
PIGMENT CELL RESEARCH, 2006, 19 (02) :112-124